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ABSTRACT: The development of new, effective, and safe drugs
to treat cancer remains a challenging and time-consuming task due
to limited hit rates, restraining subsequent development efforts.
Despite the impressive progress of quantitative structure−activity
relationship and machine learning-based models that have been
developed to predict molecule pharmacodynamics and bioactivity,
they have had mixed success at identifying compounds with
anticancer properties against multiple cell lines. Here, we have
developed a novel predictive tool, pdCSM-cancer, which uses a
graph-based signature representation of the chemical structure of a
small molecule in order to accurately predict molecules likely to be
active against one or multiple cancer cell lines. pdCSM-cancer represents the most comprehensive anticancer bioactivity prediction
platform developed till date, comprising trained and validated models on experimental data of the growth inhibition concentration
(GI50%) effects, including over 18,000 compounds, on 9 tumor types and 74 distinct cancer cell lines. Across 10-fold cross-
validation, it achieved Pearson’s correlation coefficients of up to 0.74 and comparable performance of up to 0.67 across independent,
non-redundant blind tests. Leveraging the insights from these cell line-specific models, we developed a generic predictive model to
identify molecules active in at least 60 cell lines. Our final model achieved an area under the receiver operating characteristic curve
(AUC) of up to 0.94 on 10-fold cross-validation and up to 0.94 on independent non-redundant blind tests, outperforming alternative
approaches. We believe that our predictive tool will provide a valuable resource to optimizing and enriching screening libraries for
the identification of effective and safe anticancer molecules. To provide a simple and integrated platform to rapidly screen for
potential biologically active molecules with favorable anticancer properties, we made pdCSM-cancer freely available online at http://
biosig.unimelb.edu.au/pdcsm_cancer.
■ INTRODUCTION
Cancer is the second leading cause of death globally, responsible
for almost 10 million deaths yearly, according to the World
Health Organization.1 Despite the evolution of cancer chemo-
therapy for different tumor types,2,3 most existing drugs have
many limitations, including undesirable side effects, the lack of
efficacy, toxicity, and resistance against current cancer
therapy.4,5 This has driven the widespread and continuous
search for new effective anticancer treatments while remaining a
significant challenge to overcome.6
One limitation of current screening strategies has been the
inefficiencies of current phenotypic and high-throughput
screening approaches, which only screen a limited portion of
available chemical space and have low hit rates of 0.01−1%, and
the size of the molecules screened is a constraint, which may
limit or complicate subsequent optimization efforts in terms of
both pharmacokinetic and pharmacodynamic properties.7−9
Optimizing and enriching these libraries for compounds more
likely to demonstrate anticancer potential, and promising
pharmacokinetics, could significantly reduce the associated
time and development costs. Toward this, several studies have
applied statistical and machine learning approaches in order to
identify potential anticancer molecules.5,10,11 This has been
greatly aided by the Development Therapeutics Program
(DTP), which experimentally evaluated thousands of small
molecules tested against NCI-60 human cancer cell lines.12 For
example, leveraging this data, Li and Huang used machine
learning to identifying molecules with anticancer activity,10 and
Kumar and colleagues had some success developing quantitative
structure−activity relationship (QSAR) models against 16
pancreatic cancer cell lines, regardless of the biological targets
of the drugs.13 One of their limitations, however, was that no
information was provided regarding the physicochemical
properties and structural features that a molecule should have
to enhance the bioactivity and cytotoxicity against various
pancreatic cell lines.
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Previous studies have shown that applying the graph-based
signature approach is an efficient way to describe chemical,
biomolecular data sets and design chemical molecules. In
addition, graph-based signatures have been currently used to
represent three-dimensional (3D) space of chemical entities as
well as to accurately predict their pharmacokinetics, toxicity, and
bioactivity properties.14−22 Using this concept, we have
developed a new machine learning tool, pdCSM-cancer (Figure
1), which can accurately predict small molecules that are likely to
be active against one or multiple cancer types over different cell
lines.
■ RESULTS AND DISCUSSION
Quantitative Correlation of Molecular Properties with
Biological Activity. A large and diverse data set of the
experimental activity of thousands of molecules against the
National Cancer Institute (NCI) 60 cancer cell lines was
collected from the literature. Figure S1 represents the
distribution of physicochemical properties for compounds
with anticancer activity. Most of the active and inactive
molecules obeyed Lipinski’s rule of five,24 indicating a bias in
the primary screening libraries for anticancer drug discovery.
To explore what makes a good hit while screening for
anticancer compounds, we assessed whether there was an
association between physicochemical properties and biological
activity. We observed that the active molecules tended to have a
slightly larger topological polar surface area (TPSA), more rings,
and a slightly larger number of hydrogen bond acceptors and
donors (using a two-sample Kolmogorov−Smirnov test, p-value
< 2.2e-16) compared to the inactive molecules (Figure S1). This
may represent a significant increase in the molecular complexity
Figure 1. pdCSM-cancer workflow. The developed approach has four major stages. (1) In data curation, small-molecule activity data (in terms of
GI50%) were obtained from DTP of NCI23 for nine different tumor types (74 cancer cell lines); (2) in feature engineering, two types of features were
calculated: (i) graph-based signatures, which represent the chemical geometry and physicochemical properties of small molecules, and (ii) compound
general properties and pharmacophores; (3) these features were then employed to train and test predictive models using supervised learning, and
model optimization was carried out, via greedy feature selection; (4) finally, the models with the best performance were made available through a user-
friendly web interface.
Figure 2. Molecular substructure enrichment in compounds with anticancer activity. (A) The first fragment occurred 6.50% in active and 1.78% in
inactive molecules, tested against the CNS, ovarian, and non-small-cell lung cancer cell panels (lines). (B) The second fragment occurred 5.95% in
active and 1.86% in inactive molecules, tested against leukemia, renal, and breast cancer cell panels. (C) The third fragment was identified in 6.58% in
active and 1.70% in inactive molecules, tested against prostate (not shown), melanoma, and colon cancer cell lines. (D) The fourth fragment was found
in 11% in active and 2.0% in inactive compounds, tested against small lung cancer cell lines.
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needed for optimizing potency and safety while designing
anticancer molecules.
Molecular Substructure Mining. In order to better
understand and interpret what makes up a molecule with
anticancer properties, we investigated common substructures
enriched in compounds with anticancer activity using MoSS.25
We explored substructure enrichment in a focused group
comprising active molecules, in comparison to a complementary
set (inactive molecules). In addition, the common substructure
enrichment was examined in the NCI-60 panels of cell lines
represented as nine distinct tumor types: leukemia, central
nervous system (CNS), renal, melanoma, colon, ovarian, breast,
lung, and prostate cancers.
Four common substructures were found to be occurring more
frequently in active molecules in comparison with inactive
molecules. The active molecules were found to be enriched in
benzene rings. The analysis presented in Figure 2 depicts the
commonly occurring substructures.
The first substructure (Figure 2A) is naphthalene, which is a
simple polycyclic aromatic hydrocarbon. Chemical compounds
derived from naphthalene are known to display different
biological activities, which include anticancer, antibacterial,
and anti-inflammatory activities.26 Additionally, several studies
have reported that naphthalene derivatives could induce cell
apoptosis in many types of cancer cells, such as colon cancer
cells, breast cancer cells, melanoma cells, and lung cancer
cells.26−28
The second substructure (Figure 2B) is the lactone structure.
Several compounds containing lactone exhibited remarkable in
vitro cytotoxic activity as well as apoptosis against non-small cell
lung, breast, and leukemia cancer cell lines.29,30
The third substructure (Figure 2C) is the N-methyl aniline
structure, which is used for designing Src kinase inhibitors. Small
molecules containing N-methyl aniline have exhibited potential
anticancer activity against different tumor types.31
The fourth substructure (Figure 2D) is quinoline, which is an
aromatic heterocyclic compound. It consists of a benzene and a
pyridine ring. Also, it is a part of the known topoisomerase II
inhibitor voreloxin.32 Derivatives of quinoline have shown
significant anticancer activity by different mechanisms including
apoptosis and growth inhibition through cell cycle arrest.33
Predicting Small Molecules with Anticancer Activity.
To predict anticancer pharmacodynamic properties of small
molecules, as well as their bioactivity, different supervised
machine learning algorithms were applied to train a classification
predictive model, using evidence from the distance-based graph
signatures and more general physicochemical properties. A
diverse data set of 18,369 experimentally characterized
molecules with anticancer properties screened against NCI-60
cancer cell lines were employed, including 8565 active and 9804
inactive molecules.
In the NCI-60 DTP project, molecule screening was carried
out in two stages to discover potential anticancer activity.
Initially, all compounds were screened against 60 cancer cell
lines at 5−10 molar concentrations. Furthermore, compounds
exhibiting significant growth inhibition were evaluated on the
NCI-60 cell panel at five different concentration levels.
After feature selection, our final model achieved an accuracy
of 0.86 on 10-fold cross-validation, with an area under the ROC
curve (AUC) of 0.90 and a precision of 0.85 (Figure 3A),
significantly outperforming the alternative approach CDRUG
developed using the same data (Table 1). This was comparable
to the performance across the non-redundant blind test,
achieving an accuracy of 0.77, AUC of 0.84, and precision of
Figure 3. Receiver operating characteristic (ROC) curves of the pdCSM-cancer classification model. Our predictive model accurately identified active
molecules with AUC> 0.84 on cross-validation and blind tests. (A) Performance of pdCSM-cancer on the CDRUG data. (B) Performance of pdCSM-
cancer predictor on the updated NCI-60 data.
Table 1. Comparative Performance on Cross-Validation
between the pdCSM-cancer Classification Model and
Another Available Approach, CDRUGa
method MCC sensitivity FPR accuracy AUC
pdCSM-cancer (updated
NCI-60 data)
0.72 0.84 0.13 0.86 0.94
pdCSM-cancer (CDRUG
data)
0.70 0.85 0.15 0.86 0.90
CDRUG10 * 0.81 0.20 * 0.87
aAsterisk: MCC and accuracy predictive scores were not reported by
CDRUG, neither the prediction matrix (i.e., predicted and actual
values for each molecule).
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0.79, providing confidence in the generalizability of the final
model (Figure 3).
Furthermore, we tested the performance of our final model on
the updated NCI-60 data, where it achieved an accuracy of 0.86
on 10-fold cross-validation, AUC of 0.94, and precision of 0.84
(Figure 3B). On the non-redundant blind test, it achieved an
accuracy of 0.87, AUC of 0.94, and precision of 0.85. The model
performance was consistent on both data sets (the updated
NCI-60 and CDRUG data), which shows the robustness of the
method (Table 1).
A two-sample Kolmogorov−Smirnov test was conducted on
all the features used in the final model to determine which
distinct features of the compounds translate into anticancer
activity.We found thatmolecules with anticancer activity tended
to have a high frequency of lactone and pyridine rings (p-value <
1.9 e-07). Interestingly, the inactive compounds tended to have
a higher frequency of amides. These characteristics were further
validated by substructure mining. Figure S2 depicts the top
discriminative features of active compounds compared to
inactive compounds.
Cell Line-Specific Activity Prediction.While the perform-
ance of our approach to identify likely generic anticancer
compounds provided further confidence into the potential of
graph-based signatures to provide biological insight, cancer is
not a single disease. We therefore applied this approach to
predict the anticancer activity (GI50%) against each of the 74
specific cancer cell lines. The final models achieved Pearson’s
correlation coefficients ranging from 0.58 (for SNB-78 cell line)
to 0.74 (for P388 cell line) across 10-fold cross validation (Table
2 and Table S2 and Figures S3−S12). Similarly, Corteś-Ciriano
and colleagues modeled the 50% growth inhibition (GI50%) of
thousands of compounds screened against 59 cancer cell lines of
the NCI60 panel, and by combining chemical and biological
information, their models achieved a mean Pearson’s
correlations ranging from 0.41 (for LOCCO: leave-one-
compound-out model) and 0.88 (for LOTO: leave-one-tissue-
out model).34 The results obtained for our final models are
comparable to the performance reported previously.
Figure 4 depicts the performance in terms of predicted versus
experimental GI50% values35 for each model for 10-fold cross-
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validation, also highlighting performance on 90% of the data
(i.e., after 10% outlier removal).
To further validate the models, these were evaluated on
independent blind tests sets. The performance was observed to
be consistent between cross-validation and blind tests,
indicating the generalization capabilities of the models. For
blind tests, the models achieved Pearson’s correlations ranging
from 0.48 (DMS-273 cell line) and 0.67 (P388_ADR cell line)
(Table 2 and Figures S13−S22).
Comparison of the distributions of the predicted versus
experimental GI50% values35 for each model of the 74 specific
cancer cell lines revealed that there was a significant overlap of
compounds with an experimental −log10(GI50%) value of 4
(Figures S3−S22), indicating a low anti-proliferative activity
against all types of cancer cell lines tested, which might impose a
Figure 4. pdCSM-cancer regression performance on cross-validation. Scatter plots between experimental and predicted GI50% values, given in
−log10(molar), for each of the nine cancer cell line (panels) models are displayed. Pearson’s correlation coefficient (r) is shown for each scatter plot (in
black for 90% of the data, after 10% of outliers (depicted in red) were removed).
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bias and, as a consequence, a challenge for the regression models
in predicting anticancer activity. To account for this, a general
classifier model was built that is capable of predicting anticancer
and non-anticancer molecules, as described above. To the best
of our knowledge, this is the first effort of developing cancer cell
line-specific bioactivity predictors using the NCI-60 panels.
Compounds that are active on a given tissue type could
display similar molecular signatures against other cancer types
and their activity could be a reflection of similar chemical
structures.7 Therefore, we examined whether cancer types could
be clustered based on common molecular features between
compounds. We performed a clustering analysis based on k-
means and hierarchical agglomerative clustering on the 74
specific cancer cell lines. Interestingly, the clustering analysis
revealed that the cell lines per tissue type do not cluster together,
apart from a group of melanoma cell lines that tended to form a
small cluster. Nevertheless, even if the cell line has a distinct
identity, the properties of a given data set might be subject to
sampling biases or may not match the cancer type of origin. The
latter may be because tumors that are supposed to arise in a
particular tissue could be a metastatic lesion arising from a distal
site. Consequently, cell lines originating from such tumors might
have a different tissue type identification from that specified at
isolation, creating a cause of mislabeling.36 Figure S23 shows a
heatmap of the distinctive molecular features between different
cancer cell lines.
pdCSM-cancer Web Server. To provide the scientific
community with pdCSM-cancer functionalities, we have
implemented an easy-to-use web interface freely available at
http://biosig.unimelb.edu.au/pdcsm_cancer. Users can predict
the anticancer activity and GI50% values of their molecules of
interest by submitting either a single molecule or multiple
molecules as a batch file by presenting molecules as SMILES
strings.
Additionally, it allows users to calculate the pharmacokinetic
properties of their chosen molecules using the pkCSM tool
(Figure S24).
■ CONCLUSIONS
Here, we have presented pdCSM-cancer, an optimized graph-
based signature approach for predicting safe, efficient, and
biologically active compounds against multiple cancer types.
pdCSM-cancer is capable of quantitatively predicting small
molecules that are likely to be active against one or multiple
cancer cell lines.
Using graph-based signatures, we have built and implemented
74 regression models capable of quantitatively assessing
molecule bioactivity and a predictive classification model with
categorical outputs for predicting anticancer activity for novel
molecules as well as their physicochemical properties. We have
made pdCSM-cancer available through a user-friendly web
server at http://biosig.unimelb.edu.au/pdcsm_cancer.
We believe that pdCSM-cancer would be a valuable tool for
augmenting screening approaches to identifying novel anti-
cancer drugs, increasing hit rates and reducing costs. This will
hopefully facilitate the process of drug discovery by enabling the
rapid design and optimization of compounds with anticancer
properties.
As future work, we intend to investigate the association of
combined drugs37,38 (i.e., molecules) to improve the efficiency
of cancer treatments. Our further study would seek to
understand how the anticancer bioactivity of a certain
compound changes when it interacts with others. In addition,
to incorporate more interpretability into pdCSM-cancer, we aim
to predict not only the anticancer property for that particular
drug but also hierarchically its respective target(s).39−42 With
this, drug treatments may be more understandable in terms of
efficiency and side effects, for instance. Finally, further
development of a molecular generative model (e.g., conditional
variational autoencoder)43 will be carried out. Autoencoders
would provide the ability to test/screen drugs that are out of the
scope of the database (e.g., NCI-60). This would likely yield
novel drugs with anticancer properties, which have not been
tested yet.
■ METHODS
Data Sets. All datasets were curated from the NCI-60
Development Therapeutics Project (DTP),12 which has
thousands of small molecules analyzed against NCI-60 human
cancer cell lines. In this fashion, to develop a general bioactivity
predictor, first, a dataset of bioactive molecules with anticancer
properties were constructed from an updated version of NCI-60
data (June 2020). The data for constructing the updated version
of the anticancer bioactivity dataset can be retrieved from NCI
DTP on NCI-60 Growth Inhibition Data.23 The construction of
this first dataset was based on the same methodology used by Li
andHuang’s study10 and comprehends 12,646 active and 15,777
inactive molecules after merging with Li and Huang’s previous
benchmark data. Second, for direct comparison with the
CDRUG approach, Li and Huang’s dataset was solely employed
to test the predictive performance of pdCSM-cancer. This
benchmark data comprises 8565 active and 9804 inactive
molecules.
It is worth noting that the bioactivity in both datasets is
defined based on one dose and dose-response data. On these
dose data, a molecule is considered as inactive if the average of
the growth inhibition rate is lower than 5% at a dose of 10−5 mol
on one dose data. On the other hand, a molecule is set as active if
the average of the growth inhibition rate is higher than 50% at a
dose of 10−5 mol on dose-response data.
Experimental GI50% (50% of cell growth inhibition) values,
given in −log10(molar), for the NCI-60 human cancer cell lines
were also collected from theNCI-60Development Therapeutics
Project,38 including 15,636 experimental results against the 60
different cancer cell lines (plus 14 additional cancer cell lines)
derived from nine tumor types. This data was used as evidence to
train cell line-specific learning models for regression tasks and
assess their final predictive/generalization performance. The
negative logarithm of the GI50% values of each molecule was
combined (based on NCI identifiers) for each cancer cell line to
generate tissue-specific data sets, which included at least 7677
unique molecules.
The bioactivity and GI50% datasets were divided into a non-
redundant training (80%) and blind test (20%) to train and
evaluate the predictive/generalization performance of the
predictive models used for the classification and regression
tasks. Molecules were clustered on Morgan/Circular finger-
prints with the Butina algorithm using Tanimoto similarity (at a
0.6 similarity level) using RDKit46 to make sure that similar
molecules were either on training or test sets. All datasets used in
this study are available at http://biosig.unimelb.edu.au/pdcsm_
cancer/data.
Graph-Based Signatures to Represent Small Mole-
cules. Graph modeling is a well-established mathematical
representation used to model chemical entities, which relies on
the structural fingerprints of molecular descriptors to determine
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the relationships between molecular structures and their
biological activities. These signatures have been proven to be a
general and powerful tool to model the physicochemical
properties of small molecules14 and other biological enti-
ties.16,44,45 We have previously proposed the concept of graph-
based signatures to represent protein structure geometry and the
molecular interactions with their binding partners as
graphs.19,46−49 These were successfully used and adapted to
train and test many different machine learning models, such as
the prediction and optimization of pharmacokinetic and toxicity
properties using a pkCSM tool.15 We employed and adapted
these distance-based signatures to model small-molecule
chemistry, enabling the prediction of their anticancer properties.
There are two key components of the graph-based signatures:
(i) compound physicochemical properties obtained via the
RDKit cheminformatics library50 and (ii) distance-based
signatures, described as a cumulative distribution function of
distances in atoms defined based on their corresponding
physicochemical properties (pharmacophores) (Table S1).
The distance-based patterns are encoded in a small-molecule
graph-based signature that was adjusted from the Cutoff
Scanning matrix method.51 In this approach, each dimension
of the molecular signature expresses the number of atoms
(characterized by pharmacophore class) within a particular
distance in the graph. The cost of the shortest path is based on
the shortest distance between any two nodes in the molecular
graph, calculated by Johnson’s algorithm. It is described as the
total weights of the edges on the path, where all the edges are
considered to have unitary weight (Figure S25). Hence, the
value of the shortest path is expressed as the number of edges in
it.15 Using the graph-based signature approach, a total of 264
features were obtained and used to train and test the predictive
models.
It is worth noting that there are other ways to represent small
molecules in order to build machine learning for molecular
prediction. For instance, one of the current approaches is based
on deep feature generation through graph neural networks
(GNN).52 Although being a successful approach, GNN-
generated features have, as a major drawback, the lack of an
inherent interpretability, which is a natural aspect from the
graph-based signatures. Accordingly, graph-based signature
features were first preferred for pdCSM-cancer than others. In
future work, other types of features (e.g., deep GNN features)
will be incorporated into the pdCSM-cancer models after
carrying out an analysis of their predictive benefits.
Feature Selection. Selecting the best set of features to train
predictive models is known to be a challenging problem. A
bottom-up greedy feature selection method was employed to
reduce the redundancy, noise, and low representativity of the
264 graph-based signature features obtained to represent
molecules.
This method starts with zero features, by considering each
feature independently, adds them one by one in accordance to a
machine learning model, and keeps only the set of features with
the most prominent performance metric (e.g., Pearson’s
correlation coefficient) on that particular model.
Model Selection and Evaluation. To obtain a predictive
classification model, we first evaluated several learning
algorithms, including random forest, extremely randomized
trees, gradient boosting, k-nearest neighbors, and extreme
gradient boosting, using the implementation available on the
Scikit-learn library.53 Random forest was the one with the best
predictive performance on 10-fold cross-validation over the
training set after greedy feature selection. Therefore, the random
forest classifier was used as our final model.
Random forest is a powerful ensemble-learning algorithm that
generates multiple models of decision trees from a randomly
chosen subset of the training set. It then aggregates the votes
from various decision trees to determine the most voted class of
the test object.54 The predictive model was trained and assessed
using 10-fold cross-validation and a non-redundant blind test.
Themodel performance was evaluated using different evaluation
metrics, which include accuracy, precision, and the area under
the ROC curve (AUC). AUC is an effective measure to evaluate
a model’s performance in a classification task at various
threshold settings. It is based on the ROC curve, which is
plotted with the true positive rate (TPR) against the false
positive rate (FPR). Higher AUCmeans that themodel is robust
and capable of discriminating between the two classes: active
and inactive. AUC uses values between 0 and 1. Therefore, an
accurate model would have an AUC of 1, and an AUC of 0.5
indicates that the model is a random classifier.
In the regression counterpart of this work, we also analyzed
different regression supervised learning methods to build 74
models for predicting the GI50% values, including gradient
boosting, extreme gradient boosting, random forest, extremely
randomized trees, and adaptive boosting, which were applied via
the Scikit-learn library.55 Pearson’s correlation coefficient,
RMSE, and Kendall’s correlation coefficient were employed to
select the model with the best performance (Table S2) after
greedy feature selection. A 10-fold cross-validation procedure
and non-redundant blind test were employed to evaluate the
performance of the predictive models. To examine the effect of
potential outliers, the model’s performance was evaluated on
100% and also on 90% of the data, which can be interpreted as
the full data set minus the 10% worst predicted data points (i.e.,
the points that fall away from the regression line). For the
datasets, the ensemble methods, extremely randomized trees
and random forest, were found to be the best performing
algorithms (Table S2).
Substructure Mining. Molecular Substructure miner
(MoSS)25 was used to investigate the substructure enrichment
in molecules with anticancer activity. We examined frequent
substructures in a focused group including active molecules, in
comparison to a complementary set (inactive molecules). To
find the frequency of substructure enrichment in a set of
molecules, we used a minimum support (frequency) of 10%
(default) in the focus set and a 2% of the maximum support
(frequency) in complement. Also, the threshold for the split was
specified as 0.5.
Web Server Development. The web server front end was
developed via Bootstrap framework version 3.3.7, and the back
end was built in Python 2.7 with the use of the Flask framework
(version 0.12.3). It is hosted on a Linux server running Apache.
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